Open AccessLowered Cancer Risk With ACE Inhibitor s/ ARB s: A Population‐Based Cohort Study
Author(s) -
Chiang YiYing,
Chen KuenBao,
Tsai TungHan,
Tsai WenChen
Publication year - 2014
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12228
Subject(s) - medicine , hazard ratio , propensity score matching , confidence interval , cancer , retrospective cohort study , ace inhibitor , cohort study , angiotensin converting enzyme , cohort , population , oncology , environmental health , blood pressure
There are conflicting reports on cancer risk associated with angiotensin‐converting enzyme ( ACE) inhibitor s/angiotensin receptor blockers ( ARB s). This retrospective cohort study was conducted to analyze the risk of cancer development in patients who received ACE inhibitor s/ ARB s as treatment for essential hypertension. Using the Taiwan National Health Insurance Research Database, 297,688 eligible study patients with essential hypertension were identified. According to their antihypertensive prescriptions, the study patients were stratified into an ACE inhibitor group, an ARB group, or a control group. After matching, participants were observed for the occurrence of cancer. In the ACE inhibitor group compared with the control group, the hazard ratio was 0.51 (95% confidence interval, 0.39–0.68). In the ARB group compared with the control group, the hazard ratio was 0.8 (95% confidence interval, 0.65–0.97). Regular use of ACE inhibitor s/ ARB s was not associated with an increased risk of cancer development and was actually found to decrease overall cancer risk in this study.